Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | YAP1 | P46937 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838082 | 0.96 | HCAR3 (0.76) | HCAR3HPGDALDH1A1LMNAMEN1 | |
| SCHEMBL23970849 | 0.94 | HCAR3 (0.75) | HCAR3HPGDALDH1A1LMNAMEN1 | |
| SCHEMBL22725401 | 0.90 | HCAR3 (0.60) | HCAR3HPGDALDH1A1LMNAMEN1 | |
| SCHEMBL22725418 | 0.89 | HCAR3 (0.68) | HCAR3HPGDALDH1A1LMNAMEN1 | |
| SCHEMBL7179451 | 0.89 | HCAR3 (0.68) | HCAR3HPGDALDH1A1LMNAMEN1 | |
| SCHEMBL7179457 | 0.89 | HCAR3 (0.68) | HCAR3HPGDALDH1A1LMNAMEN1 | |
| SCHEMBL2027705 | 0.88 | HCAR3 (0.68) | HCAR3ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15320045 | 0.88 | HCAR3 (0.68) | HCAR3ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15321173 | 0.88 | HCAR3 (0.68) | HCAR3HPGDALDH1A1LMNAMEN1 | |
| SCHEMBL32660016 | 0.88 | HCAR3 (0.68) | HCAR3HPGDALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597381-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190135782-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-05-09 | — | — | US | disclosed |
| US-10233171-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2019-03-19 | — | — | US | disclosed |
| US-20170233370-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-17 | — | — | US | disclosed |
| US-9580398-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150079035-A1 | Compounds, Compositions, and Methods For Modulating Ferroptosis and Treating Excitotoxic Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-19 | — | — | US | disclosed |
| WO-2013152039-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-7304085-B2 | Nitrogen-containing heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1631554-A2 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES FOR THE TREATMENT OF HCV-INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-07-14 | — | — | US | disclosed |
| WO-2004108687-A2 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES FOR THE TREATMENT OF HCV-INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1429759-A4 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6803374-B2 | INHIBIT THE RNA-DEPENDENT RNA POLYMERASE (RDRP) ENCODED BY HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| EP-1429759-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | Bristol-Myers Squibb Company (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040067976-A1 | Compounds useful for treating Hepatitis C virus | PRIESTLEY ELDON SCOTT (US) | 2004-04-08 | — | — | US | disclosed |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-17 | — | — | US | disclosed |
| WO-2003026587-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | EIF2AK2, MAVS, NSUN3 | HCAR3 3867/4885HPGD 2982/4885ALDH1A1 3657/4885 |
| US-20040067976-A1 | Compounds useful for treating Hepatitis C virus | OAT, HAVCR2, GOT1 | HCAR3 1973/4885HPGD 1108/4885ALDH1A1 102/4885 |
| US-10597381-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | AIFM2, GPX1, GPX4 | HCAR3 783/4885HPGD 776/4885ALDH1A1 1311/4885 |
| US-20150079035-A1 | Compounds, Compositions, and Methods For Modulating Ferroptosis and Treating Excitotoxic Disorders | AIFM2, GPX1, GPX4 | HCAR3 904/4885HPGD 516/4885ALDH1A1 897/4885 |
| US-20170233370-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, GPX4 | HCAR3 783/4885HPGD 776/4885ALDH1A1 1311/4885 |
| US-10233171-B2 | Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders | AIFM2, GPX1, GPX4 | HCAR3 783/4885HPGD 776/4885ALDH1A1 1311/4885 |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | EIF2AK2, MAVS, NSUN3 | HCAR3 3867/4885HPGD 2982/4885ALDH1A1 3657/4885 |
| US-20190135782-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | AIFM2, GPX1, GPX4 | HCAR3 783/4885HPGD 776/4885ALDH1A1 1311/4885 |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | OAT, HAVCR2, GOT1 | HCAR3 1973/4885HPGD 1108/4885ALDH1A1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.